about
Burden of illness of rheumatoid arthritis in Latin America: a regional perspectiveA phase 2 randomized, double-blind study of AMG 108, a fully human monoclonal antibody to IL-1R, in patients with rheumatoid arthritisTuberculosis and other opportunistic infections in tofacitinib-treated patients with rheumatoid arthritisChallenges in the management of rheumatoid arthritis in developing countries.Reaching those most in need: a scoping review of interventions to improve health care quality for disadvantaged populations with osteoarthritis.Treat to target strategy in rheumatoid arthritis: real benefits.Current therapies in rheumatoid arthritis: a Latin American perspective.Safety of Tofacitinib in the Treatment of Rheumatoid Arthritis in Latin America Compared With the Rest of the World Population.Peficitinib, a JAK Inhibitor, in Combination With Limited Conventional Synthetic Disease-Modifying Antirheumatic Drugs in the Treatment of Moderate-to-Severe Rheumatoid Arthritis.Prevalence of musculoskeletal disorders and rheumatic diseases in Cuenca, Ecuador: a WHO-ILAR COPCORD study.Prevalence of musculoskeletal manifestations and related disabilities in a Peruvian urban population living at high altitude. COPCORD Study. Stage I.Lupus patients in an emergency unit. Causes of consultation, hospitalization and outcome. A cohort study.Factors associated with chloroquine-induced retinopathy in rheumatic diseases.Rheumatoid arthritis in Latin America. Important challenges to be solved.Association study of LMP gene polymorphisms in Mexican patients with spondyloarthritis.Biosimilar drugs in Mexico: position of the Mexican College of Rheumatology, 2012.Health related quality of life in rheumatoid arthritis, osteoarthritis, diabetes mellitus, end stage renal disease and geriatric subjects. Experience from a General Hospital in Mexico.Report on the First PANLAR Rheumatology Review Course Rheumatoid Arthritis: Challenges and Solutions in Latin America.The Social Gap Index and the prevalence of osteoarthritis in the community: a cross-sectional multilevel study in Mexico.Cultural adaptation and validation of the Quality of Life Questionnaire of the European Foundation for Osteoporosis (QUALEFFO) in a Mexican population.Prevalence of antinuclear antibodies in 3 groups of healthy individuals: blood donors, hospital personnel, and relatives of patients with autoimmune diseases.Familial aggregation of systemic lupus erythematosus, rheumatoid arthritis, and other autoimmune diseases in 1,177 lupus patients from the GLADEL cohortResponse to: 'Clinical evidence guidelines in systemic lupus erythematosus: revaluation' by ScheinbergValidity of retrospective disease activity assessment in systemic lupus erythematosusFirst Latin American clinical practice guidelines for the treatment of systemic lupus erythematosus: Latin American Group for the Study of Lupus (GLADEL, Grupo Latino Americano de Estudio del Lupus)-Pan-American League of Associations of RheumatologOmega-3 fatty acids in rheumatoid arthritis: an overviewTumor necrosis factor-alpha promoter polymorphisms in Mexican patients with spondyloarthritisPrescription rheumatology practices among Mexican specialistsTumor necrosis factor-alpha -308 promoter polymorphism contributes independently to HLA alleles in the severity of rheumatoid arthritis in MexicansTowards elucidation of the epidemiology of the rheumatic diseases in Mexico. COPCORD studies in the communityCushing's disease as a cause of severe osteoporosis: a clinical challengeSteroid therapy in clinically stable but serologically active systemic lupus erythematosus prevents severe disease flaresCosts of the standard rheumatology care in active rheumatoid arthritis patients seen in a tertiary care center in Mexico City[Clinical utility of specialized immunologic testing in rheumatology in a secondary level hospital in Mexico][Present and future of rheumatic diseases in Latin America. Are we prepared to face them?]Association of anti-Ro52, anti-Ro60 and anti-La antibodies with diagnostic, clinical and laboratory features in a referral hospital in Jerez, SpainMyelitis transverse in Sjögren's syndrome and systemic lupus erythematosus: presentation of 3 casesDemographic and clinical characteristics of chikungunya patients from six Colombian cities, 2014-2015
P50
Q26798332-E4B4B7DD-8185-45E7-994D-01212F7996A6Q34346378-3421DBC2-D966-422C-95E2-4D72C182C134Q36968737-9CBD58F8-662A-4B98-BCAF-B732F284A4A6Q37265648-3DC03A00-EAD7-4DC7-B799-8DDC05AA09E4Q37789007-1989A97C-4A4F-4C5D-99AA-FEEE6F5671BCQ38044114-3CB0FCEF-FE75-41B0-BC55-38B687210598Q38075662-5132B8FF-ABF5-45CE-BABD-DF674AADF1DFQ38987176-C4A4AF53-A71F-45F1-86F8-BE5A8EC53887Q39020448-F60B860C-5001-4789-B706-D67A0EEE157AQ40362740-5862C3CE-1818-468B-90A5-2B72A299FE9EQ40451119-94B9BE32-8651-415F-93DE-2C2D31028CFFQ40613454-5A12B19B-5546-4DF6-87C2-778CCB8B00ACQ41914430-7DBC8849-08EB-42FF-AA9A-33FE9A7D2BEEQ43204160-17FBE043-DEA8-459F-A49F-C185AC81A12BQ45189930-CAA191AB-35EB-4F48-AD05-17FD756021D1Q46742106-9B49DE86-E1C6-46CF-B215-32247F642F88Q48076861-ED399C37-52E9-492A-96F4-5477B7A022C3Q50765306-1D913D3C-3AD9-4888-A025-D38F18E1DDF3Q51053130-AAE2E0FD-940B-463C-9001-897A063E09C3Q51901246-A75CC824-FF12-4991-8BB9-1759CFAEE14BQ53354424-0F2BE869-24B5-45E4-92BE-4910C6842D0FQ57461958-067F12BB-DE97-4248-AAC0-1BEA459E95BEQ57795575-26B69E00-8C57-43F8-9482-1E8637B2287FQ57910631-22E6D519-F995-4D1B-B645-115346D34B5AQ64924819-E8052CA2-5BAD-4577-BCA7-53E59BD3B63FQ74774826-993D99F6-514A-4347-803B-69FAA94C1318Q79284500-DD5163D9-5441-47D3-A9C5-723855B66705Q79916647-80C9FBF1-960C-41D5-864E-EDFF1C8DFABAQ81428872-3B1C405A-C9E2-498C-AFCA-D1D1C23E2C51Q83085008-82EEE4F2-1A54-422E-B508-D0057E615F80Q83662504-6D37D8D5-D495-4C1F-ACBE-EC784A3971D0Q84240254-E3923451-BE59-4D1B-89A6-104435E3FFF1Q84600106-D2F3BBDE-74C9-4AD2-85F8-D85ECD26CB8EQ84600271-EA6F9AA4-69AE-4D83-99E5-693175B4B5E9Q84957258-603C8477-3B8A-445D-806A-B6F22FC1A857Q87004596-161A0B8F-542E-4BBC-8231-1B65D8C991B7Q88048347-76B204C5-0581-446E-AAFC-32D9DB0FE547Q90833743-96DA567D-0EFB-4121-A59F-3342124C1AC2
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Mario Humberto Cardiel
@ast
Mario Humberto Cardiel
@en
Mario Humberto Cardiel
@es
Mario Humberto Cardiel
@nl
Mario Humberto Cardiel
@sl
type
label
Mario Humberto Cardiel
@ast
Mario Humberto Cardiel
@en
Mario Humberto Cardiel
@es
Mario Humberto Cardiel
@nl
Mario Humberto Cardiel
@sl
prefLabel
Mario Humberto Cardiel
@ast
Mario Humberto Cardiel
@en
Mario Humberto Cardiel
@es
Mario Humberto Cardiel
@nl
Mario Humberto Cardiel
@sl
P106
P21
P31
P496
0000-0002-2731-9180